Literature DB >> 3606330

Auditory P300 in borderline personality disorder and schizophrenia.

S P Kutcher, D H Blackwood, D St Clair, D F Gaskell, W J Muir.   

Abstract

Using three sets of clinical criteria to define borderline personality disorder (BPD), P300 (P3) and other long-latency auditory event-related electroencephalographic potentials were measured in 22 subjects with BPD, 32 subjects with other personality disorders, 29 schizophrenics, 22 depressives, and 74 volunteer controls. The patients with BPD were found to differ from patients with nonborderline personality disorders, having a longer P3 latency and smaller P3 amplitude. Long-latency event-related potentials were similar in the BPD and schizophrenic groups and did not differentiate patients with BPD with a concurrent diagnosis of schizotypal personality disorder from those without schizotypal personality disorder. The P3 latency and amplitude changes distinguished the BPD and schizophrenic groups from normal controls, those with major depressive disorder, and those with nonborderline personality disorders. These findings suggest that though some patients with BPD may have depressive symptomatology, they share with schizophrenics a dysfunction of auditory neurointegration.

Entities:  

Mesh:

Year:  1987        PMID: 3606330     DOI: 10.1001/archpsyc.1987.01800190065010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

1.  Event-related potential P300 microstate topography during visual one- and two-dimensional tasks in chronic schizophrenics.

Authors:  K Kochi; T Koenig; W K Strik; D Lehmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

2.  The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.

Authors:  S Kutcher; G Papatheodorou; S Reiter; D Gardner
Journal:  J Psychiatry Neurosci       Date:  1995-03       Impact factor: 6.186

3.  Lateralized P3 deficit in schizotypal personality disorder.

Authors:  M A Niznikiewicz; M M Voglmaier; M E Shenton; C C Dickey; L J Seidman; E Teh; R Van Rhoads; R W McCarley
Journal:  Biol Psychiatry       Date:  2000-10-01       Impact factor: 13.382

4.  "Schizoid" personality in childhood: auditory P300 and eye tracking responses at follow-up in adult life.

Authors:  D H Blackwood; W J Muir; H M Roxborough; M R Walker; R Townshend; M F Glabus; S Wolff
Journal:  J Autism Dev Disord       Date:  1994-08

5.  Event-related potentials in methamphetamine psychosis during an auditory discrimination task. A preliminary report.

Authors:  A Iwanami; I Suga; N Kato; Y Nakatani; T Kaneko
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

6.  Response inhibition in borderline personality disorder: event-related potentials in a Go/Nogo task.

Authors:  M Ruchsow; G Groen; M Kiefer; A Buchheim; H Walter; P Martius; M Reiter; L Hermle; M Spitzer; D Ebert; M Falkenstein
Journal:  J Neural Transm (Vienna)       Date:  2007-09-21       Impact factor: 3.575

7.  Time course of facial emotion processing in women with borderline personality disorder: an ERP study.

Authors:  Natalie A Izurieta Hidalgo; Rieke Oelkers-Ax; Krisztina Nagy; Falk Mancke; Martin Bohus; Sabine C Herpertz; Katja Bertsch
Journal:  J Psychiatry Neurosci       Date:  2016-01       Impact factor: 6.186

Review 8.  DNA markers and biological vulnerability markers in families multiply affected with schizophrenia.

Authors:  D Blackwood; D St Clair; W Muir
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

9.  Waves earlier than P3 are more informative in putative subcortical dementias: a study with mapping and neuropsychological techniques.

Authors:  N P Verma; C D Nichols; M F Greiffenstein; R P Singh; D Hurst-Gordon
Journal:  Brain Topogr       Date:  1989       Impact factor: 3.020

Review 10.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.